Cell line · CVCL_1392
Lu-65
Cancer cell line, Homo sapiens. Lung giant cell carcinoma. 34 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Lu-65. Cell lines, record CVCL_1392. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1392
On this page
Cell line
As Cellosaurus gives it.
- Name
- Lu-65
- Accession
- CVCL_1392
- RRID
- RRID:CVCL_1392
- Synonyms
- LU-65M, LU-65, LU65, Lu65, Lu 65, C-Lu-65, C-Lu65
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 64Y
- Category
- Cancer cell line
- Diseases
- Lung giant cell carcinoma (NCIt C4452)
- Derived from
- Lung (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers34
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| FOXD3 Is Functionally Linked to NF-κB Signaling in KRAS G12C-Mutant NSCLC Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A first-in-class EGFR-directed KRAS G12V selective inhibitor. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan. | Hum Cell | 2024 | Cellosaurus cites it | PubMed |
1 to 10 of 34
See all 34 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | Lu-65A | CVCL_3012 | Cell lines | |
| Derived from it | Lu-65B | CVCL_3013 | Cell lines | |
| Derived from it | Lu-65C | CVCL_3014 | Cell lines |
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| JCRB | JCRB0079 | JCRB | |
| RCB | RCB1967 | RCB | |
| TKG | TKG 0442 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1392
GET https://conductscience.org/api/cell-lines/v1/CVCL_1392/papers?page=2